Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

María Alsina; Guillermo Villacampa; Carlos E. de Andrea; Ana Vivancos; Mariano Ponz‐Sarvisé; Virginia Arrazubi; Paula Jiménez‐Fonseca; Marc Díez; Enrique Sanz‐García; Eva Martínez de Castro; Raquel Guardeño; Mariona Calvo; Cristina Bugés; Federico Longo; Vı́ctor Navarro; Eduardo García‐Galea; Alena Gros; María C. Ochoa; Álvaro López‐Janeiro; Sandra Sánchez‐Gregorio; Claudia Herrero; Ibone Labiano; Maria Vila‐Casadesús; Dario López; Raluca Alexandru; Susana Muñoz; Josep Tabernero; Ignacio Melero

doi:10.1158/1078-0432.29568175

Key Points

MAIN FINDING: A phase II study investigates the effects of avelumab in combination with chemotherapy for gastric cancer.
KEY EVIDENCE: Baseline patient characteristics are detailed for the intention-to-treat (ITT) and modified ITT (mITT) populations.
APPROACH: The study focuses on patient outcomes post-therapy, analyzing data from the MONEO study.
SIGNIFICANCE: Insights from this trial could inform future treatments for patients with resectable gastric cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase II study examines avelumab plus chemotherapy in resectable gastric cancer and gastroesophageal junction cancer, suggesting its potential benefit in treatment.

Abstract

Baseline patient characteristics in the ITT and mITT populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alsina et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6eb https://doi.org/10.1158/1078-0432.29568175

View at Publisher

Ask AI

Bookmark

Share

Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers